The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

caliperls.com

Total Raised

$37.09M

Investors Count

2

Deal Terms

3

Caliper Life Sciences Funding, Caliper Life Sciences Valuation & Caliper Life Sciences Revenue

8 Fundings

Caliper Life Sciences's latest funding round was a Acq - P2P for on September 8, 2011.

Caliper Life Sciences's latest post-money valuation is from September 2011.

Sign up for a free trial to see Caliper Life Sciences's valuations in September 2011 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

9/8/2011

Acq - P2P

$99M

0

FY undefined

1

8/14/2000

PIPE

$99M

0

FY undefined

0

12/15/1999

IPO

$99M

0

FY undefined

10

6/5/1998

Private Equity

$99M

0

FY undefined

0

5/1/1998

Acquired

0

FY undefined

0

Date

9/8/2011

8/14/2000

12/15/1999

6/5/1998

5/1/1998

Round

Acq - P2P

PIPE

IPO

Private Equity

Acquired

Amount

$99M

$99M

$99M

Investors

Valuation

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

10

0

0

Financials

Income Statement

Income Statement

12/31/2021

12/31/2020

12/31/2019

Total Sales (or Revenue)

$99M

$99M

$99M

Cost of Goods Sold (COGS) including Depreciation and Ammortization

$99M

$99M

$99M

Gross Income

$99M

$99M

$99M

SG&A Excluding Other

$99M

$99M

$99M

Other Operating Expense

$99M

$99M

$99M

EBIT (Operating Income)

$99M

$99M

$99M

Non-Operating Income (Expense)

$99M

$99M

$99M

Interest Expense

$99M

$99M

$99M

Usual Expense

$99M

$99M

$99M

Pretax Income

$99M

$99M

$99M

Income Taxes

$99M

$99M

$99M

Equity in Earnings of Affiliates Income

$99M

$99M

$99M

Other After Tax Adjustments

$99M

$99M

$99M

Consolidated Net Income

$99M

$99M

$99M

Minority Interest Expense

$99M

$99M

$99M

Net Income From Continuing Operations

$99M

$99M

$99M

Preferred Dividends

$99M

$99M

$99M

Net Income Available to Common

$99M

$99M

$99M

EPS (Recurring)

$99M

$99M

$99M

EPS - Basic - Before Extraordinaries

$99M

$99M

$99M

EPS (Diluted)

$99M

$99M

$99M

EBITDA

$99M

$99M

$99M

Stock Option Compensation Expense

$99M

$99M

$99M

Operating Lease Expense

$99M

$99M

$99M

Foreign Currency Adjustment (Net)

$99M

$99M

$99M

Income Statement

Total Sales (or Revenue)

Cost of Goods Sold (COGS) including Depreciation and Ammortization

Gross Income

SG&A Excluding Other

Other Operating Expense

EBIT (Operating Income)

Non-Operating Income (Expense)

Interest Expense

Usual Expense

Pretax Income

Income Taxes

Equity in Earnings of Affiliates Income

Other After Tax Adjustments

Consolidated Net Income

Minority Interest Expense

Net Income From Continuing Operations

Preferred Dividends

Net Income Available to Common

EPS (Recurring)

EPS - Basic - Before Extraordinaries

EPS (Diluted)

EBITDA

Stock Option Compensation Expense

Operating Lease Expense

Foreign Currency Adjustment (Net)

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Balance Sheet

Balance Sheet

12/31/2021

12/31/2020

12/31/2019

Cash & Short Term Investments

$99M

$99M

$99M

Inventories

$99M

$99M

$99M

Other Current Assets

$99M

$99M

$99M

Total Current Assets

$99M

$99M

$99M

Net Property, Plant & Equipment

$99M

$99M

$99M

Total Investments and Advances

$99M

$99M

$99M

Long-Term Note Receivable

$99M

$99M

$99M

Intangible Assets

$99M

$99M

$99M

Deferred Tax Assets

$99M

$99M

$99M

Other Assets

$99M

$99M

$99M

Total Assets

$99M

$99M

$99M

Short Term Debt (including Current Portion of Long Term Debt)

$99M

$99M

$99M

Accounts Payable

$99M

$99M

$99M

Income Tax Payable

$99M

$99M

$99M

Other Current Liabilities

$99M

$99M

$99M

Total Current Liabilities

$99M

$99M

$99M

Long Term Debt

$99M

$99M

$99M

Provision for Risks Charges

$99M

$99M

$99M

Deferred Tax Liabilities

$99M

$99M

$99M

Other Liabilities

$99M

$99M

$99M

Total Liabilities

$99M

$99M

$99M

Non-Equity Reserves

$99M

$99M

$99M

Preferred Stock - Carrying Value

$99M

$99M

$99M

Common Equity

$99M

$99M

$99M

Total Shareholders Equity

$99M

$99M

$99M

Accumulated Minority Interest

$99M

$99M

$99M

Total Equity

$99M

$99M

$99M

Total Liabilites & Stockholders Equity

$99M

$99M

$99M

Book Value Per Share

$99M

$99M

$99M

Tangible Book Value Per Share

$99M

$99M

$99M

Balance Sheet

Cash & Short Term Investments

Inventories

Other Current Assets

Total Current Assets

Net Property, Plant & Equipment

Total Investments and Advances

Long-Term Note Receivable

Intangible Assets

Deferred Tax Assets

Other Assets

Total Assets

Short Term Debt (including Current Portion of Long Term Debt)

Accounts Payable

Income Tax Payable

Other Current Liabilities

Total Current Liabilities

Long Term Debt

Provision for Risks Charges

Deferred Tax Liabilities

Other Liabilities

Total Liabilities

Non-Equity Reserves

Preferred Stock - Carrying Value

Common Equity

Total Shareholders Equity

Accumulated Minority Interest

Total Equity

Total Liabilites & Stockholders Equity

Book Value Per Share

Tangible Book Value Per Share

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Financials

Cash Flow

Cash Flow

12/31/2021

12/31/2020

12/31/2019

Net Income (Starting Line)

$99M

$99M

$99M

Depreciation

$99M

$99M

$99M

Deferred Taxes & Investment Tax Credit

$99M

$99M

$99M

Other Funds (Non Cash)

$99M

$99M

$99M

Funds from Operations

$99M

$99M

$99M

Extraordinary Item

$99M

$99M

$99M

Changes in Working Capital

$99M

$99M

$99M

Net Operating Cash Flow

$99M

$99M

$99M

Capital Expenditures

$99M

$99M

$99M

Net Assets From Acquisitions

$99M

$99M

$99M

Sale of Fixed Assets and Businesses

$99M

$99M

$99M

Purchase or Sale of Investments

$99M

$99M

$99M

Other Uses

$99M

$99M

$99M

Other Sources

$99M

$99M

$99M

Net Investing Cash Flow

$99M

$99M

$99M

Cash Dividends Paid

$99M

$99M

$99M

Change in Capital Stock

$99M

$99M

$99M

Issuance or Reduction of Debt, Net

$99M

$99M

$99M

Net Financing Active Other Cash Flow

$99M

$99M

$99M

Net Financing Cash Flow

$99M

$99M

$99M

Exchange Rate Effect

$99M

$99M

$99M

Miscellaneous Funds

$99M

$99M

$99M

Net Change in Cash

$99M

$99M

$99M

Free Cash Flow

$99M

$99M

$99M

Cash Flow

Net Income (Starting Line)

Depreciation

Deferred Taxes & Investment Tax Credit

Other Funds (Non Cash)

Funds from Operations

Extraordinary Item

Changes in Working Capital

Net Operating Cash Flow

Capital Expenditures

Net Assets From Acquisitions

Sale of Fixed Assets and Businesses

Purchase or Sale of Investments

Other Uses

Other Sources

Net Investing Cash Flow

Cash Dividends Paid

Change in Capital Stock

Issuance or Reduction of Debt, Net

Net Financing Active Other Cash Flow

Net Financing Cash Flow

Exchange Rate Effect

Miscellaneous Funds

Net Change in Cash

Free Cash Flow

12/31/2021

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2020

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

12/31/2019

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

All numbers in millions (except EPS)Market Data by Xignite

Caliper Life Sciences Deal Terms

3 Deal Terms

Caliper Life Sciences's deal structure is available for 3 funding rounds, including their Acq - P2P from September 08, 2011.

Round

Acq - P2P

Series B

Series A

Funding Date

$99M

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

$99M

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acq - P2P

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Caliper Life Sciences Investors

2 Investors

Caliper Life Sciences has 2 investors. Paycheck Protection Program invested in Caliper Life Sciences's Loan funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

4/9/2020

4/9/2020

1
Loan

Government

DC

Air Water

Subscribe to see more

Corporation

Japan

First funding

4/9/2020

Last Funding

4/9/2020

Investor

Air Water

Rounds

1
Loan

Subscribe to see more

Board Seats

Type

Government

Corporation

Location

DC

Japan

Caliper Life Sciences Acquisitions

1 Acquisition

Caliper Life Sciences acquired 1 company. Their latest acquisition was Xenogen on August 11, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/11/2006

Other Venture Capital

$99M

$112.15M

Acquired

Date

8/11/2006

Investment Stage

Other Venture Capital

Companies

Valuation

$99M

Total Funding

$112.15M

Note

Acquired

Sources

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

O
Ocimum Biosolutions

Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).

Biocom Logo
Biocom

Biocom works to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs, and create value-driven purchasing programs.

S
SideroGen

SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

Van Andel Institute Logo
Van Andel Institute

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.

Harvard Bioscience Logo
Harvard Bioscience

Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.